Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NovoCure Limited before investing.

In this article, we go over a few key elements for understanding NovoCure Limited’s stock price such as:

• NovoCure Limited’s current stock price and volume
• Why NovoCure Limited’s stock price changed recently
• Upgrades and downgrades for NVCR from analysts
• NVCR’s stock price momentum as measured by its relative strength

About NovoCure Limited (NVCR)

Before we jump into NovoCure Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Want to learn more about NovoCure Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NovoCure Limited.

NovoCure Limited’s Stock Price as of Market Close

As of December 02, 2025, 3:18 PM, CST, NovoCure Limited’s stock price was $11.105.

NovoCure Limited is down 4.92% from its previous closing price of $11.680.

During the last market session, NovoCure Limited’s stock traded between $10.790 and $11.840. Currently, there are approximately 111.91 million shares outstanding for NovoCure Limited.

NovoCure Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

NovoCure Limited Stock Price History

NovoCure Limited’s (NVCR) price is currently down 13.31% so far this month.

During the month of December, NovoCure Limited’s stock price has reached a high of $12.580 and a low of $10.790.

Over the last year, NovoCure Limited has hit prices as high as $34.130 and as low as $10.700. Year to date, NovoCure Limited’s stock is down 62.73%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused NovoCure Limited Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 01, 2025, there were 3 analysts who downgraded NovoCure Limited’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate NovoCure Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NovoCure Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

NovoCure Limited’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NovoCure Limited (NVCR) by visiting AAII Stock Evaluator.

Relative Price Strength of NovoCure Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 01, 2025, NovoCure Limited has a weighted four-quarter relative price strength of -7.95%, which translates to a Momentum Score of 31 and is considered to be Weak.

Want to learn more about how NovoCure Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

NovoCure Limited Stock Price: Bottom Line

As of December 2, 2025, NovoCure Limited’s stock price is $11.105, which is down 4.92% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NovoCure Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.